Pricing Log in Create free account

Vyome Holdings, Inc. (HIND) vs TScan Therapeutics, Inc. (TCRX)

Vyome Holdings, Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Vyome Holdings, Inc. and TScan Therapeutics, Inc. are of similar size ($12.3M and $11.4M). TScan Therapeutics, Inc. grew revenue faster over the last twelve months: 2.15% against −67.1%. TScan Therapeutics, Inc. has the higher net margin (−1,655.4% vs −8,711.7%) and the lower return on invested capital (−4,588.2% vs 0.00%). Across the 18 metrics below, TScan Therapeutics, Inc. leads on 11 and Vyome Holdings, Inc. on 7.

Valuation

Metric HIND TCRX Biotechnology median
P/E n/m n/m 10.60
P/S 86.52 3.29 9.40
P/B 1.54 0.34 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.37 0.66
EV/Sales 124.04 (6.19) 9.02
Earnings yield (223.64%) (505.56%) (32.88%)
Free cash flow yield (49.67%) (506.23%) (23.13%)

Profitability

Metric HIND TCRX Biotechnology median
Gross margin 52.77% 100.00% 68.51%
Operating margin (9,184.82%) (1,695.15%) 0.00%
Net margin (8,711.71%) (1,655.35%) 0.00%
Free cash flow margin (4,298.00%) (1,665.18%) 0.00%
Return on equity (172.10%) (95.80%) (51.96%)
Return on assets (124.23%) (50.09%) (46.06%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric HIND TCRX Biotechnology median
Revenue growth (TTM) (67.10%) 2.15% 6.76%
EPS growth (last fiscal year) 99.92% 12.28% 29.88%
Revenue growth, 5-year CAGR (50.98%) 56.92% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HIND TCRX Biotechnology median
Debt to equity 0.00 0.47 0.00
Current ratio 4.37 3.37 4.97
Net debt to EBITDA 0.48 0.90 1.01

Dividend

Metric HIND TCRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric HIND TCRX Biotechnology median
Market cap 11.44m 12.32m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack